Program
precemtabart tocentecan
Also written as “M9140” and “Precemtabart tocentecan”.
Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms, led by Merck KGaA, Darmstadt, Germany.
Furthest: phase 3, since Apr 16, 20264 company-led studies, 3 open or runningNext primary completion: Dec 23, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 43 open or running | phase 3since Apr 16, 2026 | Jul 15, 2022 | Dec 23, 2027phase 2 · NCT06710132 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 15, 2022First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT05464030 · 220 enrolled · United States, Canada, Japan and more
- Nov 22, 2024Phase 2 study in Stomach NeoplasmsNCT06710132 · 184 enrolled · United States, Australia, Austria and more
- Jan 13, 2025Phase 1 study in Colorectal NeoplasmsNCT06806046 · 12 enrolled · China
- Apr 16, 2026Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07549412 · 1,020 planned · United States, Argentina, Australia and more
Ahead
- Dec 23, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT06710132
- Oct 16, 2029Primary completion: phase 3 study in Colorectal NeoplasmsNCT07549412
TargetBeta
CEACAM5 →read by rule
“An antibody-drug conjugate (ADC) composed of precemtabart, a human immunoglobulin G1-kappa monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA), ”NCIt, by rule
Other programs on CEACAM5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-CEACAM5 Antibody-drug Conjugate BMS-986490rule | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-CEACAM5 Antibody-drug Conjugate IBI3020rule | Innovent Biologics | phase 1 | 1 |
| tusamitamab sonditecan | Pfizer | phase 1 | 1 |
| RO7821657rule | Hoffmann-La Roche | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07549412Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Oct 16, 2029 | 1,020 |
| NCT06806046Colorectal Neoplasms · China | 1 | Completed | Sep 23, 2026 | 12 |
| NCT06710132Stomach Neoplasms · United States, Australia, Austria and more | 2 | Active, not recruiting | Dec 23, 2027 | 184 |
| NCT05464030Colorectal Neoplasms · United States, Canada, Japan and more | 1 | Active, not recruiting | Oct 23, 2026 | 220 |
How it is read
Names in the registry
- “M9140”, 4 entries
- “Precemtabart tocentecan”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 3 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.